Ontology highlight
ABSTRACT:
SUBMITTER: Charnigo RJ
PROVIDER: S-EPMC6440678 | biostudies-literature | 2019 Mar
REPOSITORIES: biostudies-literature
Charnigo Robert J RJ Beidler David D Rybin Denis D Pittman Debra D DD Tan Beesan B Howard Jo J Michelson Alan D AD Frelinger Andrew L AL Clarke Nicholas N
Clinical and translational science 20181231 2
This phase Ib study randomized patients with stable sickle cell disease (SCD) aged 18-65 years to twice-daily PF-04447943 (a phosphodiesterase 9A inhibitor; 5 or 25 mg) or placebo, with/without hydroxyurea coadministration, for up to 29 days. Blood samples were collected at baseline and various posttreatment time points for assessments of PF-04447943 pharmacokinetics (PKs)/pharmacodynamics (PDs). Change from baseline in potential SCD-related biomarkers was evaluated. Of 30 patients, 15 received ...[more]